We Are Randox | Randox mentor recognised at QUB 2018 Placement Awards
We Are Randox | Randox mentor recognised at QUB 2018 Placement Awards
A senior manager at global healthcare diagnostics company Randox Laboratories has been recognised by Queen’s University Management School with a prestigious award.
Presented with the accolade at the Management School Placement Awards Event 2018, Financial Controller Mary McAllister was nominated by QUB student Bronagh McCarron who had completed her placement year at Randox in the company’s finance office.
Mary McAllister, Senior Financial Controller at Randox Laboratories, and recipient of the QUB Management School Mentor Recognition Award, commented;
“As an incredibly hard-working, diligent and enthusiastic placement student, Bronagh was a valued member of the Randox Finance Team. I’m delighted therefore, that this Mentor Recognition Award represents that equally, Bronagh really valued her time with us at Randox. With extensive training, support, trust and encouragement, we’re proud to be playing a significant part in the development of the next generation of QUB graduates.”
The Mentor Recognition Award seeks to acknowledge individuals within QUB’s placement employer partners who establish an organised, supportive and beneficial placement environment, which engages, motivates and inspires students during their time in industry.
Bronagh McCarron, Randox Finance Placement and Student at QUB Management School said;
“Throughout my placement year Mary was always incredibly approachable for any problems or queries I had. Asking questions was always encouraged and I never felt like I couldn’t speak up to seek guidance on any of the tasks I had within the Randox Finance department. It’s thanks to Mary and all of my Randox colleagues that I enjoyed my placement year so much and now have more faith in my abilities as I return to university for my final year of studies.”
The Queen’s Management School Placement Programme has been running for more than 25 years, with the aim of empowering students to develop their employability skills. Students are encouraged to identify their career aspirations, reflect on their skills, and find areas of development in order to meet the needs of an ever competitive graduate labour market.
Bronagh added;
“During my time with the Accounts team at Randox, I worked on both the Accounts Receivable for our headquarters office, and on the Accounts Payable for our Randox Teoranta site in Dungloe, Donegal. This variety of work gave me plenty of exposure to the different aspects of Accounts Management. I was involved in communication with both customers and suppliers from a wide range of companies, from which no one query was the same. It has massively increased my confidence working in a business environment.”
Dr. Peter FitzGerald, Founder and Managing Director of Randox Laboratories, commented;
“At Randox we are great advocates of placement during a student’s time in education. It gives Randox the opportunity to work with ambitious and bright young people from across Northern Ireland and in turn we can help to nurture their potential and provide them with industry experience. I’m very proud therefore that Mary’s dedication and commitment to the placement students placed in her care has been formally recognised by Queen’s University Belfast and on behalf of everyone at Randox would like to pass on our congratulations for being awarded this impressive prize.”
For further information about the QUB Management School Placement Awards please contact Randox PR by emailing randoxpr@randox.com
We Are Randox | Christmas Jumper Day in aid of Save the Children
It was beginning to look a lot like Christmas at Randox today as colleagues donned their favourite festive knit in aid of Save the Children’s Christmas Jumper Day.
Staff members across Randox UK got involved in the winter fundraiser – from Crumlin to London and Liverpool to Holywood.
If you’d like to donate to Save the Children, please text TEAM RANDOX to 70050 and a £2 donation will go to Save the Children plus your standard message rate.
#WeAreRandox
Randox Biosciences and Metabolic Syndrome
The Evidence Evolution is a fully automated immune-analyser with random access. The machine has the capability to process up to 2640 tests per hour with up to 44 analytes screened per biochip. With a wide range test menu Randox can offer the market the service they expect with state-of-the-art intuitive touchscreen software and advanced precision bio-drive robotics.
Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.
Metabolic disease is very common. Studies state that the serious health condition affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.
Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.
1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:
- Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)
- Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater
- HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
- Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater
- Fasting glucose of 100 mg/dL or greater
There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.
Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.
Metabolic Syndrome Array I
- Ferritin
- Interleukin-6 (IL-6)
- Insulin
- Leptin
- Plasminogen Activator Inhibitor-1 (PAI-1)
- Resistin
- Tumour Necrosis Factor α (TNFα)
Metabolic Syndrome Array II
- Adiponectin
- C-reactive Protein (CRP)
- Cystatin C
For more information on our Evidence Series or Metabolic Syndrome Range of Assays, contact us at EvidenceSeries@randox.com
Ā£700,000 UK government investment in Randox R&D
A £700,000 UK Research and Innovation investment into manufacturing processes at Randox means patients could benefit from quicker, cheaper and more consistent diagnosis of diseases.
The announcement comes exactly one year after the government launched its modern Industrial Strategy – the long-term plan to boost productivity by backing businesses to create high-quality, well-paid jobs in every corner of the United Kingdom.
The Industrial Strategy Challenge Fund (ISCF) award, administered by UK Research and Innovation (UKRI), will allow Randox Laboratories to further develop its state-of-the-art ‘freeze-drying’ technology which enables the components of vital diagnostic kits to be manufactured, stored and transported more effectively, producing better and speedier diagnoses.
For the first time it also allows this complicated manufacturing process to be carried out in the UK rather than having to be outsourced to countries such as the United States, bringing more jobs and economic growth. These new genomic analysis tools also have the potential to make a major impact in the global fight against antimicrobial resistance by identifying and quickly sharing information about resistant microbial strains.
More in-depth analysis of biomarkers in blood and other bodily fluid levels will allow better, quicker diagnosis of cancers and a range of other diseases, ranging from respiratory infections to sepsis, such as blood poisoning.
The Secretary of State for Northern Ireland said:
“I am delighted to announce a £700,000k UK Government investment in Randox, a multinational life sciences company in County Antrim. This funding will bring significant benefits to Randox’s vital medical diagnostics and help create well-paid manufacturing jobs in Northern Ireland.
“A year-on from the launch of our Modern Industrial Strategy, this investment highlights the great progress we are making to boost productivity by backing leading businesses and creating high-quality jobs in every corner of the United Kingdom.”
John Penrose, Minister of State for Northern Ireland, who visited Randox today to mark the new investment, said:
“Everyone always says the UK needs more high-tec, high-value added manufacturing and the high-skilled, high-waged jobs it brings. But Randox are actually doing it right here in Northern Ireland. This is properly world leading, cutting-edge industry and I’m delighted that today’s money is helping bring the vision to life.”
Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented:
“Innovative diagnostic technologies are not only capable of diagnosing disease and ill-health at the earliest possible stage, but they also have a real potential to advance personalised medicine. Our commitment to developing new and exciting breakthroughs in science, technology, engineering and manufacturing is therefore matched only, by our passion to transform the life of the patient. Randox is leading the way in moving from a one-size-fits-all approach towards decisions, practices, and products tailored to the needs of the individual and the Industrial Strategy Challenge Fund award brings us one step closer to realising that aim.”
Funded through UK Research and Innovation, the award forms part of the ISCF Early Diagnosis and Precision Medicine programme, focusing on the use of diagnostic information and genetic analysis to drive more personalised healthcare. Innovate UK, now part of UK Research and Innovation, has supported Randox extensively since 2010, helping grow and scale an innovative diagnostics company who are now distributing their products all over the world.
The announcement comes after the government’s announcement of the Life Sciences Sector Deal that will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of the government’s modern Industrial Strategy. The deal signals a vote in confidence in UK industry, with global biopharmaceutical company UCB investing around £1 billion in research and development.
For further information please contact Randox PR by emailing randoxpr@randox.com
The Gift of Health: FREE Specialised Test with every Everyman or Everywoman purchased in December
This December, treat your friends and family to the greatest gift of all. The gift of health.
Throughout the month, Randox Health are offering a free Specialised Test, Cough, Cold & Flu, with every Everyman or Everywoman Programme purchased.
Examining up to 150 different indicators of health in your body! The programmes are among the most advanced in the world with our Signature Programme being the most advanced, examining up to 350 different indicators of disease and ill-health. This is due to our advanced technology.
The perfect gift, or perhaps Christmas treat for yourself? These 12-month programmes are guaranteed to give you the most advanced picture available of your current health status.
This month, each programme also comes with a free Cough, Cold & Flu check worth £100.
What is the Cough, Cold and Flu check?
In a world where warnings about antibiotic resistance make daily headlines, Randox Health is helping people take back control.
Antibiotics are used to prevent and treat antibiotic infections. But they don’t work for everything. Taking them when we don’t need them can enable dangerous bacteria that lives inside us to become resistant. That means if you need antibiotics in the future, they may not work. As the NHS says, this puts you and your family at serious risk.
Only bacterial infections can be treated with antibiotics, so finding out what’s behind your infection is essential.
With the Randox Health Cough, Cold and Flu test one swab can detect and identify the cause of 21 respiratory infections in just five hours. With this knowledge, you will find out what’s treatment is going to be appropriate for you.
Take the guesswork out of getting better and book your Cough, Cold and Flu test either as a standalone check or for free with or Everyman or Everywoman Programme.
Specialised tests are available at our clinics in London, Liverpool, Holywood and Crumlin, and also through our innovative mobile health clinic. Gift cards can be purchased from as little as £20.
To find out more about the offer or to purchase the most thoughtful of Christmas presents – a gift card for the ‘gift of health’ – please phone our team on 0800 2545 130. You can also drop them an email. info@randoxhealth.com
Detecting the earliest possible signs of type 2 diabetes
Randox Laboratories is this month driving awareness of diabetes and the need for early and accurate diagnosis to enable patients to take preventive action before the condition worsens.
Diabetes UK have stated that diabetes is the fastest growing health threat of our times and an urgent public health issue. Statistics show that since 1996, the number of people living with diabetes has more than doubled. It has been estimated that there are 1.1 million people living with diabetes in the UK that have yet to be diagnosed, including 84,836 people in Northern Ireland.
According to Diabetes UK around 700 people a day are diagnosed with diabetes, which equates to one person every two minutes. If nothing changes, it is estimated that diabetes will affect one in ten people by 2040. This will raise diabetes prevalence from 415 million to 642 million by 2040. With current treatment taking up almost 9% of the annual NHS budget – roughly £8.8bn a year – the implications for future healthcare budgets are clear if this dangerous trend persists.
The good news however, is that recent research has found that type 2 diabetes is preventable through lifestyle changes. The NHS recently released the UK’s National Diabetes Prevention Programme which is aimed at tackling the increasing growing threat of diabetes.
However, following a warning raised by an Oxford University study, which looked into efforts of this Prevention Programme, it was found that it is unlikely to have much impact because the blood tests used were inaccurate at detecting pre-diabetes – the stage at which diabetes is reversible.
The blood tests used in the National Diabetes Prevention Programme were only effective at detecting diabetes at a stage when damage had already been done.
At Randox, we have developed a number of tests that can help detect the earliest possible signs of diabetes, often before symptoms have even manifested – including a pioneering test for the hormone Adiponectin.
Assessing Adiponectin levels allows doctors to calculate a patient’s levels of visceral fat – a dangerous, internal fat stored around organs. This deep fat, which is not visible to the naked eye, is linked to health problems including Type-2 diabetes.
Low levels of adiponectin equate to high levels of visceral fat which can be combated by improving your diet, exercise habits and even stress levels. Given that 70% of Type-2 diabetes can be prevented by lifestyle changes, there is strong correlation that by detecting low levels of Adiponectin and taking corrective and preventive action, it could result in a decrease in the numbers of people who develop the life-altering condition.
In addition to a test for the Adiponectin biomarker, Randox Biosciences have created a Metabolic Syndrome Array that measures 12 markers associated with metabolic syndrome and cardiovascular disease. Metabolic Syndrome is a is a group of cardiovascular risk factors that affects over 20% of adults and results in a person being three times more likely to have a stroke or heart attack, and five times more likely to develop diabetes.
Ultimately, we would like to see all medical professionals who are at the forefront of patient care armed with the most accurate diagnostic tools available. Updating traditional practice may not be easy but we believe it is imperative to do so, if we are to effectively challenge this global epidemic.
Randox remains focused on providing early diagnoses and preventing illnesses by providing innovative diagnostics tests that will continue to revolutionise the healthcare landscape.
For further information, please contact Randox PR by emailing randoxpr@randox.com or phoning 028 9442 2413.
Randox Teoranta set to host Science, Engineering and Manufacturing Career Open Day on Christmas Eve
Do you have a flair for science? Are you an electronic, mechanical or software engineering expert? Or, perhaps, you are a mastermind of manufacturing know-how. There are world-leading careers on offer for world-leading candidates at Randox Teoranta in Dungloe this December.
That’s the message that global diagnostics firm Randox Teoranta wants to send to students, graduates and experienced professionals alike as it opens its doors to the public once again on Monday 24th December 2018.
Held from 9am to 12noon, the morning is an opportunity for those interested in science, engineering, software development and manufacturing roles in Donegal to have a tour of the state-of-the-art facility and chat with Randox Teoranta staff members about the careers on offer.
Randox Teoranta is particularly passionate about attracting back those who have left Ireland to find careers further afield due to lack of opportunities in their particular vocations. Dream careers in science, engineering and manufacturing are available on the doorstep in Dungloe.
Dr. Ciaran Richardson, Head of Research & Development at Randox Teoranta, commented;
“At Randox Teoranta, we’re constantly pushing the boundaries of healthcare and diagnostic capabilities, allowing us to offer world-class career opportunities in the heart of Donegal.
“Our scientists are working on a range of research projects which will lead to quicker diagnoses of conditions such as stroke, gastrointestinal disorders and chronic kidney disease. In 2016, our scientists even developed a pioneering new test to determine a patient’s risk of developing Alzheimer’s disease.
“There are also opportunities for software developers, electronic & embedded systems engineers, validation and mechanical engineers as our technology continues to advance to accommode our scientific breakthroughs.
“Our manufacturing department also boasts a number of competitive roles which are essential to Randox Teoranta’s continuation as a world leader in healthcare diagnostics and associated technology.
“There are fantastic career opportunities here in one of the most beautiful parts of the world – and the quality of life is second-to-none.”
There are a wide variety of career opportunities available at Randox Teoranta. From placement opportunities for college and university students to graduate roles in a variety of fields, young scientists and engineers have the opportunity to get their ‘big break’ on the career ladder with a globally-recognised company.
There are also opportunities for experienced and driven individuals looking for a smart career move. Randox Teoranta offer competitive salaries, career progression, personal development and the opportunity to work in a cutting-edge company paving the way in ground-breaking global health diagnostics.
Healthcare shouldn’t be one-size-fits-all. Neither should your career.
Randox Teoranta’s Open Morning will take place on Monday 24th December 2018 from 9:00 until 12:00 at Randox Teoranta, Meenmore, Dungloe, Co. Donegal.
Students, graduates and experienced professionals are welcome to visit along with their family and friends. Potential candidates are welcome to bring their CV on the day or email it to recruitment@randoxteoranta.com.
Booking is not required, however, more information, including directions, can be found by searching Randox at www.eventbrite.ie.
More information about the open day can also be found by contacting +353 7495 22600 or emailing RandoxPR@randox.com.
Randox Biosciences and Familial Hypercholesterolemia (FH)
Familial Hypercholesterolemia (FH) is a genetic disorder where the child is born with extremely high cholesterol levels. FH can trace back through several generations. Cholesterol is vital for the normal function of the human body therefore, it is important to ensure the cholesterol levels don’t get too high because it can result in early onset cardiovascular disease. 1
The FH Foundation states an interesting fact that 1 in 250 people worldwide have FH and over 90% of these people have not been properly diagnosed 2. Majority of these people won’t know they have FH disease until they have a heart attack!
However, there are no clear symptoms if someone has FH until it is too late and the damage has been done. The warning signs include the following:1
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Gray-white cholesterol deposits around the corneas
A study in 2008 by the British Heart Foundation found that people with FH who are diagnosed and treated before they develop heart disease live as long people who don’t have FH 4. This theory emphasis the importance of getting early diagnosis to prevent long-term problems. Treatment to prevent cardiovascular disease involves taking medication prescribed by the doctor and making lifestyle changes including; modifying diet, increasing exercise, quit smoking, decrease drinking alcohol and ensure the patient gets regular sleep.
Randox offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time allowing results to be reported within days compared to NHS waiting lists which can be substantially longer. The two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes. The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing with NGS. The genetic analysis for FH mutations allows for more accurate diagnosis compared to lipid profiling.
Randox can help using the award-winning Biochip Analyser to achieve early and appropriate treatment for those with FH resulting those to adopt a healthier lifestyle and taking cholesterol-lowering medication, risk of heart disease to live a longer and healthy life!
Familial Hypercholesterolemia (FH) Arrays I & II:
- LDLR – 38 mutations
- APOB – 1 mutation
- PCSK9 – 1 mutation
To find out more about the products that we offer email us info@randoxbiosciences.com
Reference:
https://www.healthline.com/health/familial-hypercholesterolemia#symptoms
The world’s most extensive Drugs of Abuse Test Menu
Randox Toxicology offers the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing market influences and develop assays for current and novel drugs trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
| DoA II | ||
| Buprenorphine | Ketamine | Oxycodone I |
| Creatinine | LSD | Oxycodone II |
| Fentanyl | MDMA | Propoxyphene |
| Generic Opioids | Methaqualone | – |
The Evidence Series of immunoassay analysers are powered by Biochip Array Technology and combine the latest technological advances for drug residue detection using immunoassay principles. The Drugs of Abuse II panel is available for both the Evidence and the Evidence Investigator analysers. The Evidence has a throughput of 90 samples per hour, testing up to 44 tests per sample. The Evidence is a fully automated batch immunoanalyser, allowing for 3960 tests per hour, while the Evidence Investigator is a semi-automated, bench top analyser with testing capabilities of 2376 tests in 70 minutes.
To find out more about our Biochip Array Technology and our Evidence Series analysers, visit www.randoxtoxicology.com, or email us at info@randoxtoxicology.com
Tackling Worldwide Drugs of Abuse
Throughout November, we’ve been highlighting how the Randox clinical teams – Randox Rx series, Randox Reagents and Randox QC – are aiding the fight against drugs of abuse.
Drugs of Abuse are a growing problem worldwide and represent a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle. It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.
The abuse of drugs is one of the most pressing issues in the United States of America. Drug abuse not only affects the individual, but also can have far-reaching consequences that affect family, employment, personal health, health care systems, local communities, and society as a whole.
- Misuse of illicit drugs affects society through secondary costs incurred such as crime, reduced productivity at work, and health care expenses.
- Substance abuse costs the US health care system about $11 billion, with overall costs reaching $193 billion.
- Substance abuse and addiction also affects other areas of life and can cause broken families, destroyed careers, death due to negligence or accident, domestic violence, physical abuse and child abuse.
- Drug abuse and addiction changes the chemistry of your brain. The longer you use your drug of choice, the more damage is caused and it becomes more difficult to return to ‘normal’ during drug rehabilitation.
- In 2013, 22.7 million Americans needed treatment for a substance use disorder – almost 9% of the population over the age of 12. Only about 2.5 million received treatment as a specialist facility with 20% of admissions for opiate addication treatment and 17% for the treatment of marijuana abuse.
To find out more about how Randox is helping in the fight against Drugs of Abuse, please visit https://www.randox.com/drugs-of-abuse/ or for more information about Randox RX, Randox Reagents or Randox QC, please email marketing@randox.com.
